Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

May 03 • 04:00PM ET

110.01

Dollar change +0.72
Percentage change 0.66	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB COWZ VBR VXF VHT IJJ IWR FXH

Index	-	P/E	23.93	EPS (ttm)	4.60	Insider Own	3.34%	Shs Outstand	62.26M	Perf Week	0.50%
Market Cap	6.94B	Forward P/E	5.30	EPS next Y	20.74	Insider Trans	0.36%	Shs Float	60.93M	Perf Month	-4.51%
Income	330.79M	PEG	5.32	EPS next Q	4.74	Inst Own	91.48%	Short Float	6.08%	Perf Quarter	-10.49%
Sales	3.84B	P/S	1.80	EPS this Y	1.37%	Inst Trans	-0.76%	Short Ratio	5.95	Perf Half Y	-13.61%
Book/sh	58.65	P/B	1.88	EPS next Y	11.86%	ROA	2.96%	Short Interest	3.70M	Perf Year	-19.48%
Cash/sh	28.84	P/C	3.81	EPS next 5Y	4.50%	ROE	9.41%	52W Range	103.01 - 146.70	Perf YTD	-10.56%
Dividend Est.	-	P/FCF	6.86	EPS past 5Y	-3.53%	ROI	3.73%	52W High	-25.01%	Beta	0.64
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	15.52%	Gross Margin	73.55%	52W Low	6.80%	ATR (14)	3.05
Dividend Ex-Date	-	Current Ratio	2.15	EPS Y/Y TTM	310.66%	Oper. Margin	15.83%	RSI (14)	42.69	Volatility	3.82% 2.53%
Employees	2800	Debt/Eq	1.57	Sales Y/Y TTM	2.81%	Profit Margin	8.61%	Recom	1.55	Target Price	180.78
Option/Short	Yes / Yes	LT Debt/Eq	1.40	EPS Q/Q	-124.85%	Payout	0.00%	Rel Volume	1.11	Prev Close	109.29
Sales Surprise	-5.45%	EPS Surprise	-35.87%	Sales Q/Q	1.03%	Earnings	May 01 AMC	Avg Volume	622.41K	Price	110.01
SMA20	-0.67%	SMA50	-6.01%	SMA200	-12.11%	Trades		Volume	693,768	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy	$174
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$185 → $195
Oct-09-20	Reiterated	H.C. Wainwright	Buy	$175 → $185
Sep-14-20	Resumed	JP Morgan	Overweight	$175

Show Previous Ratings

May-03-24 12:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
11:49AM	UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating (MT Newswires)
May-02-24 11:26AM	Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates (Zacks)
03:53AM	Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook (MT Newswires)
May-01-24 08:56PM	JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00PM	Loading…
07:00PM	Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:24PM	Jazz: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference (PR Newswire)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance (PR Newswire)
Apr-30-24 09:50AM	Jazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth Month (ACCESSWIRE)
Apr-24-24 04:05PM	Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 (PR Newswire)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
05:21AM	3 No-Brainer Stocks to Buy With $300 Right Now (Motley Fool)
Apr-23-24 11:15AM	Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community (ACCESSWIRE)
Apr-17-24 04:15PM	Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 (PR Newswire)
07:45AM	Loading…
Apr-10-24 07:45AM	Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting (PR Newswire)
Apr-04-24 09:15AM	Following the Money Trail: Where are Hedge Funds Investing? (Insider Monkey)
Apr-02-24 07:30AM	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer (PR Newswire)
Mar-29-24 11:30AM	Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report? (Zacks)
Mar-28-24 10:15AM	Cancer and the Combination Approach (ACCESSWIRE)
Mar-20-24 10:15AM	Jazz Pharmaceuticals Celebrates International Womens Day (ACCESSWIRE)
Mar-18-24 03:28PM	20 States with the Cheapest Weed in America (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 12:00PM	Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month (ACCESSWIRE)
10:00AM	Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 05:34PM	11 Stocks Insiders are Buying Now (Insider Monkey)
04:15PM	Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 (PR Newswire)
Mar-09-24 11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Mar-07-24 01:51PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
01:10PM	Loading…
01:10PM	Q4 2023 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
10:08AM	10 Mid-Cap Stocks with Insider Purchases (Insider Monkey)
Feb-29-24 10:45AM	Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates (Zacks) -8.33%
10:35AM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates (Zacks)
04:33PM	Jazz Pharmaceuticals PLC (JAZZ) Reports Strong Revenue Growth and Robust Pipeline Progress (GuruFocus.com)
04:29PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance (PR Newswire)
Feb-27-24 10:15PM	Q4 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:45AM	Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors (PR Newswire)
Feb-24-24 05:06AM	4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Feb-23-24 09:15AM	Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-21-24 08:50AM	Jazz Pharmaceuticals Names Eli Lillys Philip Johnson as Next CFO (The Wall Street Journal)
07:45AM	Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer (PR Newswire)
Feb-20-24 05:00PM	3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-14-24 04:15PM	Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024 (PR Newswire)
Feb-13-24 10:15AM	Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals (ACCESSWIRE)
Feb-09-24 09:15AM	How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1 (ACCESSWIRE)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
02:00AM	Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program (PR Newswire)
Feb-03-24 05:06AM	4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Jan-31-24 03:33PM	25 Most Cannabis Consuming-Countries in the World (Insider Monkey)
12:03PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024 (InvestorPlace)
Jan-22-24 05:16AM	2 Incredible Growth Stocks That Are Screaming Buys for 2024 (Motley Fool)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-13-24 05:06AM	4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-28-23 10:06PM	7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World (InvestorPlace)
Dec-22-23 12:07PM	Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals (Zacks)
11:16AM	Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study (Benzinga)
Dec-21-23 04:17PM	UPDATE 1-Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:09PM	Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:05PM	Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder (PR Newswire)
Dec-20-23 04:15PM	Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
05:21AM	3 No-Brainer Stocks to Buy With $500 Right Now (Motley Fool)
Dec-08-23 01:20PM	Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer (PR Newswire)
11:30AM	Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report? (Zacks)
09:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities (ACCESSWIRE)
Dec-01-23 09:02AM	Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting (PR Newswire)
Nov-30-23 07:45AM	Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings (PR Newswire)
Nov-29-23 11:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly (ACCESSWIRE)
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
Nov-27-23 09:49AM	5 Best Upside Stocks To Buy Now (Insider Monkey)
Nov-15-23 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Nov-14-23 12:50PM	12 Best Value Stocks To Buy Heading Into 2024 (Picked By Seth Klarman) (Insider Monkey)
02:00AM	Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders (Business Wire)
Nov-09-23 05:07PM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.14%
Nov-08-23 07:00PM	Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics (Zacks)
05:52PM	Jazz Pharmaceuticals PLC (JAZZ) Reports Solid Q3 2023 Results and Raises Revenue Guidance (GuruFocus.com)
04:42PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 12:33PM	Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics (Zacks)
07:45AM	Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers (PR Newswire)
Nov-01-23 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences (PR Newswire)
10:01AM	Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-31-23 05:42PM	10 Stocks That Will Skyrocket (Insider Monkey)
Oct-30-23 04:05PM	11 Best Long-Term Stocks To Buy For High Returns (Insider Monkey)
Oct-26-23 11:40AM	JAZZ vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
Oct-25-23 04:15PM	Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023 (PR Newswire)
08:34AM	Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength? (Zacks)
08:30AM	Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 (PR Newswire)
Oct-23-23 07:45AM	Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023 (PR Newswire)
Oct-21-23 06:38AM	Wyndham rebuffs Choice Hotels; Southwestern surges on M&A talk: 4 big deal reports (Investing.com)
Oct-20-23 10:30AM	Jazz Pharmaceuticals Said to Explore Options Including Sale (Bloomberg)
Oct-18-23 07:55AM	5 Value Stocks With High Earnings Yield to Boost Your Portfolio (Zacks)
07:45AM	Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023 (PR Newswire)
Oct-17-23 09:55AM	Does Jazz (JAZZ) Have the Potential to Rally 47.29% as Wall Street Analysts Expect? (Zacks)
04:21AM	Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-16-23 07:45AM	Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023 (PR Newswire) +5.33%

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Patricia	SVP, Chief Accounting Officer	Mar 07 '24	Sale	116.98	1,768	206,821	6,596	Mar 08 06:07 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 06 '24	Sale	119.64	1,936	231,628	8,364	Mar 08 06:07 PM
Johnson Philip L	EVP & Chief Financial Officer	Mar 01 '24	Buy	119.65	12,000	1,435,800	27,932	Mar 05 07:28 PM
Cook Jennifer E.	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:31 PM
Smith Mark Douglas	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:39 PM
Patil Neena M	EVP & Chief Legal Officer	Sep 01 '23	Sale	144.25	1,500	216,375	29,186	Sep 06 05:09 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 29 '23	Sale	143.47	142	20,373	5,986	Aug 31 06:44 PM
Patil Neena M	EVP & Chief Legal Officer	Aug 15 '23	Sale	139.59	750	104,695	30,686	Aug 17 05:21 PM
McSharry Heather Ann	Director	Aug 14 '23	Sale	138.16	1,344	185,685	16,778	Aug 15 05:52 PM
Sohn Catherine A.	Director	Aug 14 '23	Sale	138.16	1,241	171,455	14,868	Aug 15 06:02 PM
ENRIGHT PATRICK G	Director	Aug 14 '23	Sale	138.16	1,241	171,455	20,946	Aug 15 05:45 PM
O'Keefe Kenneth W	Director	Aug 14 '23	Sale	138.16	1,241	171,455	24,723	Aug 15 07:49 PM
Winningham Rick E	Director	Aug 14 '23	Sale	138.16	1,241	171,455	10,444	Aug 15 06:08 PM
Gray Peter	Director	Aug 14 '23	Sale	138.16	1,241	171,455	16,068	Aug 15 05:47 PM
Cook Jennifer E.	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 05:44 PM
RIEDEL NORBERT G	Director	Aug 14 '23	Sale	138.16	1,241	171,454	13,705	Aug 15 05:58 PM
ORiordan Anne	Director	Aug 14 '23	Sale	138.16	1,241	171,454	12,551	Aug 15 07:51 PM
Smith Mark Douglas	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 06:00 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 14 '23	Sale	138.16	158	21,829	6,128	Aug 15 05:43 PM
Mulligan Seamus	Director	Jun 08 '23	Option Exercise	81.76	4,500	367,920	1,169,300	Jun 12 04:47 PM
Carr Patricia	SVP, Chief Accounting Officer	Jun 07 '23	Sale	127.92	126	16,117	6,286	Jun 09 04:55 PM
Patil Neena M	EVP & Chief Legal Officer	Jun 01 '23	Sale	127.98	1,600	204,763	32,826	Jun 05 08:24 PM
GALA RENEE D	EVP & Chief Financial Officer	May 18 '23	Sale	131.75	6,000	790,474	35,978	May 19 08:45 PM

Open in Screener

TBPH

Theravance Biopharma Inc

May 03 • 04:00PM ET

9.46

Dollar change +0.09
Percentage change 0.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TBPH Theravance Biopharma Inc daily Stock Chart

Held by: IWM VTI VXF IWN VB IBB VBK VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-0.97	Insider Own	9.32%	Shs Outstand	48.09M	Perf Week	3.73%
Market Cap	455.59M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	49.89%	Shs Float	43.68M	Perf Month	3.50%
Income	-55.19M	PEG	-	EPS next Q	-0.25	Inst Own	101.51%	Short Float	14.72%	Perf Quarter	6.29%
Sales	57.42M	P/S	7.93	EPS this Y	35.20%	Inst Trans	-0.40%	Short Ratio	15.91	Perf Half Y	-3.57%
Book/sh	4.43	P/B	2.14	EPS next Y	38.27%	ROA	-11.16%	Short Interest	6.43M	Perf Year	-15.84%
Cash/sh	2.13	P/C	4.45	EPS next 5Y	-	ROE	-16.86%	52W Range	8.21 - 11.98	Perf YTD	-15.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.22%	ROI	-21.37%	52W High	-21.04%	Beta	0.23
Dividend TTM	-	Quick Ratio	5.39	Sales past 5Y	0.23%	Gross Margin	89.46%	52W Low	15.23%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	5.39	EPS Y/Y TTM	72.89%	Oper. Margin	-92.81%	RSI (14)	54.94	Volatility	5.16% 4.50%
Employees	99	Debt/Eq	0.23	Sales Y/Y TTM	11.84%	Profit Margin	-96.12%	Recom	1.80	Target Price	15.40
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	-11.96%	Payout	-	Rel Volume	0.83	Prev Close	9.37
Sales Surprise	-0.06%	EPS Surprise	-15.25%	Sales Q/Q	19.91%	Earnings	May 13 AMC	Avg Volume	404.08K	Price	9.46
SMA20	1.85%	SMA50	4.16%	SMA200	-1.43%	Trades		Volume	333,603	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	BTIG Research	Buy	$21
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45
Aug-17-17	Initiated	Evercore ISI	Outperform	$45
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$55
May-11-17	Reiterated	Needham	Buy	$40 → $45
Dec-21-16	Initiated	Needham	Buy	$40
Nov-03-16	Initiated	Piper Jaffray	Overweight

Show Previous Ratings

Apr-29-24 06:00AM	Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace)
07:47AM	Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Apr-10-24 06:00AM	Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 (PR Newswire)
Mar-27-24 11:30AM	Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? (Zacks)
03:59PM	Loading…
Mar-12-24 03:59PM	Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics (InvestorPlace)
Feb-28-24 10:35AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:47AM	Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates (Zacks)
Feb-26-24 05:25PM	Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:39PM	Theravance Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-22-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-14-24 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 (PR Newswire)
Jan-12-24 09:35AM	Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround (Zacks)
Jan-05-24 06:00AM	Theravance Biopharma Announces Results from the Phase 4 YUPELRI PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire) -9.98%
01:08PM	Loading…
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Dec-21-23 05:00PM	Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors (PR Newswire)
Dec-18-23 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference (PR Newswire)
Dec-07-23 11:30AM	Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-22-23 09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-16-23 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System (PR Newswire)
Nov-15-23 06:00AM	Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-13-23 08:00AM	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
Nov-08-23 02:10PM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.34%
11:35AM	Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally (Zacks)
Nov-07-23 06:09PM	Theravance Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:28PM	Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Oct-19-23 06:00AM	Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 (PR Newswire)
Sep-06-23 11:30AM	Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-31-23 05:55PM	12 High Growth Value Stocks to Buy According to Seth Klarman (Insider Monkey)
06:00AM	Loading…
Aug-29-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-28-23 06:05AM	Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Aug-09-23 06:25AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 09:54AM	Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss (Zacks)
Aug-07-23 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Theravance Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia)
Jul-24-23 06:00AM	Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 (PR Newswire)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia)
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
Jun-07-23 11:30AM	Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report? (Zacks)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-11-23 03:41PM	Takeda Moves Out From Licensing Agreement With Theravance Biopharma (Benzinga)
10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 11:34AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Theravance Biopharma First Quarter 2023 Earnings: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022) (Simply Wall St.)
May-09-23 06:00PM	Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy (PR Newswire)
09:24AM	Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates (Zacks)
May-08-23 05:55PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-04-23 10:00AM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-01-23 10:01AM	Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline (Zacks)
Apr-24-23 06:00AM	Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 (PR Newswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 07:47AM	Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Share Price Not Quite Adding Up (Simply Wall St.)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-11-23 04:05PM	Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors (PR Newswire)
Apr-10-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-31-23 12:41PM	Top Small-Cap Stocks for April 2023 (Investopedia)
11:30AM	ImmunoGen (IMGN) Down 16.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
11:30AM	Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report? (Zacks)
Mar-29-23 11:30AM	Theravance Bio (TBPH) Down 2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-10-23 06:56AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 02:50PM	Top Healthcare Stocks for March 2023 (Investopedia)
Mar-02-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-28-23 02:17PM	Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates (Zacks)
01:33PM	Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff (Benzinga)
Feb-27-23 06:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.99%
04:05PM	Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update (PR Newswire)
11:26AM	UPDATE 1-Irenic Capital urges Theravance to conduct review, add shareholder to board (Reuters)
09:00AM	Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review (Business Wire)
Feb-23-23 07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-21-23 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (PR Newswire)
Feb-16-23 10:01AM	Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-15-23 10:00AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-09-23 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-09-23 06:00AM	Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets (PR Newswire) -6.96%
Dec-25-22 09:39AM	Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago (Simply Wall St.)
Dec-07-22 11:30AM	Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report? (Zacks)
Nov-22-22 04:15PM	Theravance Biopharma, Inc. Announces Final Results of Tender Offer (PR Newswire)
Nov-18-22 06:00AM	Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer (PR Newswire)
Nov-11-22 08:20AM	We Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) Soon (Simply Wall St.)
Nov-08-22 08:34AM	Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-07-22 05:45PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer (PR Newswire)
Nov-02-22 04:30PM	Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Oct-31-22 06:00AM	Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022 (PR Newswire)
Oct-27-22 10:02AM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-26-22 10:02AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System (PR Newswire)
Sep-28-22 06:00AM	Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares (PR Newswire)
Sep-20-22 09:36AM	Company News for Sep 20, 2022 (Zacks)
Sep-19-22 02:28PM	Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings (Benzinga)
07:22AM	UPDATE: Theravance Biopharma plans $250 million capital return program; stock jumps 3% premarket (MarketWatch)
06:00AM	Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program (PR Newswire)
Sep-08-22 11:30AM	Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-06-22 06:00AM	Theravance Biopharma to Present at Upcoming Investor Conferences (PR Newswire)
Aug-14-22 08:06AM	Need To Know: Analysts Are Much More Bullish On Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenues (Simply Wall St.)

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samaha Eli	10% Owner	May 01 '24	Buy	8.75	1,499,124	13,117,335	8,511,350	May 03 04:19 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Feb 22 '24	Sale	8.71	1,254	10,922	311,733	Feb 22 08:04 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Nov 21 '23	Sale	10.29	1,378	14,180	331,206	Nov 22 06:07 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Nov 14 '23	Sale	10.22	2,482	25,366	346,839	Nov 16 06:16 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Oct 16 '23	Sale	9.03	2,482	22,412	334,321	Oct 18 06:54 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Sep 14 '23	Sale	9.89	2,482	24,547	336,803	Sep 18 06:08 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Aug 22 '23	Sale	9.47	1,807	17,112	340,566	Aug 24 06:05 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Aug 11 '23	Sale	9.99	2,322	23,197	349,746	Aug 15 06:09 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jul 14 '23	Sale	9.84	2,322	22,848	352,068	Jul 18 06:14 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	Jun 14 '23	Sale	10.69	2,322	24,822	354,390	Jun 16 06:14 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 08 '23	Sale	11.13	1,790	19,923	352,833	Jun 12 06:08 PM
GRAHAM RICHARD A	SVP, RESEARCH & DEVELOPMENT	May 15 '23	Sale	11.26	2,322	26,146	367,172	May 17 06:17 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

JAZZ

Jazz Pharmaceuticals plc

TBPH

Theravance Biopharma Inc

Upgrade your FINVIZ experience